Enzyme-resistant glucose-dependent insulinotropic polypeptide (GIP) agonists offer therapeutic potential for type 2 diabetes treatment. In addition, there is emerging evidence suggesting that GIP plays a direct role in modulating aspects of brain function. This study compared effects of dietary modification and/or twice-daily injection of the stable GIP agonist, (d-Ala(2))GIP, on metabolic control, cognitive function and hippocampal synaptic plasticity in high-fat fed mice. Young Swiss mice were maintained on high-fat diet for 155 days, at which point half of the animals were switched to standard maintenance diet. Mice were subsequently injected with (d-Ala(2))GIP (25 nmol/kg bodyweight; b.i.d.) or saline vehicle for 28 days. Both dietary i...
AIM: Glucose-dependent insulinotropic polypeptide-receptor (GIP-R) antagonism using (Pro3)GIP impr...
Glucose-dependent insulinotropic polypeptide (GIP) is a key incretin hormone, released from intestin...
Cognitive dysfunction is more common in individuals with type 2 diabetes (T2DM). Currently, glucagon...
Enzyme-resistant glucose-dependent insulinotropic polypeptide (GIP) agonists offer therapeutic poten...
Type 2 diabetes is a risk factor for Alzheimer's disease. Insulin receptor desensitisation has been ...
<div><p>Glucose-dependent insulinotropic polypeptide (GIP) is a gastrointestinal hormone that potent...
Obesity, insulin resistance and type 2 diabetes mellitus are positively correlated with neurophysiol...
Glucose-dependent insulinotropic polypeptide (gastric inhibitory polypeptide [GIP]) is an important ...
Glucose-dependent insulinotropic polypeptide (gastric inhibitory polypeptide [GIP]) is an important ...
Alzheimer's disease (AD) is a neurodegenerative disease, characterized by cognitive impairments and ...
The health and socio-economic burdens of the current diabesity epidemic present significant challeng...
Objective: Glucose-dependent insulinotropic polypeptide (GIP) is released during meals and promotes ...
Glucose-dependent insulinotropic polypeptide (GIP) is a gas-trointestinal hormone with a potentially...
GIP receptor knockout mice were shown to be protected from the development of obesity on a high fat ...
Combinatorial gut hormone therapy is one of the more promising strategies for identifying improved t...
AIM: Glucose-dependent insulinotropic polypeptide-receptor (GIP-R) antagonism using (Pro3)GIP impr...
Glucose-dependent insulinotropic polypeptide (GIP) is a key incretin hormone, released from intestin...
Cognitive dysfunction is more common in individuals with type 2 diabetes (T2DM). Currently, glucagon...
Enzyme-resistant glucose-dependent insulinotropic polypeptide (GIP) agonists offer therapeutic poten...
Type 2 diabetes is a risk factor for Alzheimer's disease. Insulin receptor desensitisation has been ...
<div><p>Glucose-dependent insulinotropic polypeptide (GIP) is a gastrointestinal hormone that potent...
Obesity, insulin resistance and type 2 diabetes mellitus are positively correlated with neurophysiol...
Glucose-dependent insulinotropic polypeptide (gastric inhibitory polypeptide [GIP]) is an important ...
Glucose-dependent insulinotropic polypeptide (gastric inhibitory polypeptide [GIP]) is an important ...
Alzheimer's disease (AD) is a neurodegenerative disease, characterized by cognitive impairments and ...
The health and socio-economic burdens of the current diabesity epidemic present significant challeng...
Objective: Glucose-dependent insulinotropic polypeptide (GIP) is released during meals and promotes ...
Glucose-dependent insulinotropic polypeptide (GIP) is a gas-trointestinal hormone with a potentially...
GIP receptor knockout mice were shown to be protected from the development of obesity on a high fat ...
Combinatorial gut hormone therapy is one of the more promising strategies for identifying improved t...
AIM: Glucose-dependent insulinotropic polypeptide-receptor (GIP-R) antagonism using (Pro3)GIP impr...
Glucose-dependent insulinotropic polypeptide (GIP) is a key incretin hormone, released from intestin...
Cognitive dysfunction is more common in individuals with type 2 diabetes (T2DM). Currently, glucagon...